You are here: Industry Insights > romark

News List

NT-300 tablets show promise in Phase III COVID-19 trial europeanpharmaceuticalreview
April 19, 2021
Initial results suggest NT-300 (nitazoxanide extended-release tablets, 300mg) reduces progression to severe illness in mild to moderate COVID-19 patients.
Lupin launches Nitazoxanide Tablets expresspharma
March 11, 2021
They are indicated in the treatment of diarrhoea caused by Giardia lamblia or Cryptosporidium parvum.
FDA Approves Romark Facility in Puerto Rico contractpharma
August 25, 2020
The facility is equipped to produce tablets, powders and other oral solid dosage forms.
Romark Initiates Trial of NT-300 for COVID-19 americanpharmaceuticalreview
August 17, 2020
Romark announced the initiation of a Phase 3 clinical trial of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets) as a treatment for mild or moderate COVID-19.
Romark Initiates Phase 3 Clinical Trials Of NT-300 for COVID-19 americanpharmaceuticalreview
April 30, 2020
Romark will initiate two clinical trials of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets) for prevention of COVID-19 and other viral respiratory illnesses in high-risk populations.
Romark Initiates Trials of NT-300 for COVID-19 Prevention contractpharma
April 28, 2020
In cell cultures, the active ingredient in NT-300, nitazoxanide, inhibits replication of a broad range of respiratory viruses, including SARS-CoV-2.